Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,265 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gastric Cancer
Interventions
capecitabine, oxaliplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Pancreatic Cancer
Interventions
ISIS 2503, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Solid Tumors
Interventions
Alpelisib, Cisplatin
Drug
Lead sponsor
Pamela Munster
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
AMV564
Biological
Lead sponsor
Amphivena Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Gastrointestinal Neoplasms, Pancreatic Neoplasms
Interventions
gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
222
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 173 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Locally Advanced Basal Cell Carcinoma
Interventions
L19IL2/L19TNF
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Kidney Cancer
Interventions
Pazopanib, Temsirolimus, Quality of Life Assessment, Benadryl
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nelfinavir (Viracept®) 1250 mg, Chemoradiation
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Colorectal Cancer
Interventions
Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
radiation therapy, oxaliplatin, fluorouracil, gemcitabine hydrochloride
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Hodgkin Disease
Interventions
Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Renal Cell Carcinoma
Interventions
HC-7366, Belzutifan
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
regorafenib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Cervical Cancer
Interventions
cisplatin, hyperthermia treatment, brachytherapy, external beam radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
53
States / cities
Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Non Small Cell Lung Cancer
Interventions
Durvalumab, Copanlisib
Drug
Lead sponsor
Zhonglin Hao
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
New Haven, Connecticut • Skokie, Illinois • Kansas City, Kansas + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Urothelial Carcinoma
Interventions
INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced May 21, 2026, 6:16 PM EDT
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
315
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced May 21, 2026, 6:16 PM EDT